Items tagged with Latent TB
Isoniazid and rifampicin monotherapy and combination therapy regimens, as well as a weekly rifapentine plus isoniazid regimen, were found to be safe and effective for preventing tuberculosis (TB) reactivation among individuals with latent TB infection (LTBI). These findings from an update to a previous network meta-analysis of randomized controlled trials (RCTs) were published in the Annals of Internal Medicine.1
Unitaid Board approves new grants to prevent TB in high-risk populations and increase TB diagnosis in children (post)
Geneva, 04 September 2017 – Unitaid’s Executive Board has approved two new grants worth a combined US$ 74 million to prevent the spread of tuberculosis (TB), the world’s leading infectious killer, in populations most at risk of contracting the disease and to increase TB diagnosis in children.
Rep. Nam In-soon of the ruling Democratic Party cited the annual Korea National Health and Nutrition Examination Survey in 2016 conducted by the Korea Centers for Disease Control and Prevention, which showed that 33.2 percent of 2,051 participants tested positive for latent TB infection.
SAN DIEGO, October 08, 2017—Discontinuation rates for the 12-dose isoniazid-rifapentine (3HP) regimen are low, and the regimen could help effectively treat latent tuberculosis infection (LTBI), confirmed a post-marketing analysis reported at IDWeek 2017.
SAN DIEGO, October 08, 2017—Findings from a retrospective chart review revealed that 3 months of rifapentine + isoniazid using directly observed therapy (3HP) resulted in a higher completion rate and no loss of follow-up vs. treatment with the traditional 9 months of isoniazid (9H) for latent tuberculosis infection (LTBI).
Testing and treatment for latent tuberculosis infection are cost-effective among U.S. residents born outside the country except for those with end-stage renal disease, according to findings published in JAMA Internal Medicine.
Self-administered therapy a viable option over directly observed therapy for latent TB infection (post)
A new study finds that self-administered therapy for latent tuberculosis infection (LTBI) may be a viable option for patients where direct medical oversight is not available. These results were published online November 7 in the Annals of Internal Medicine.
29 November 2017: The End TB Strategy introduced by the World Health Organization (WHO) and adopted by the World Health Assembly aims to reduce TB related deaths by 95% and new TB infections by 90% by 2035. Approximately one quarter to one third of the world’s population is currently infected with the M. tuberculosis bacteria and the risk of developing an active form of the disease among infected individuals is between 5 and 15 percent.
In the United States, a patient receives a new diagnosis of tuberculosis (TB) every hour, with a mortality rate of 5% to 10%, and it is estimated that 13 to 14 million people in the United States have latent TB infection (LTBI).1 More than 80% of patients develop TB years after becoming infected, clearly underscoring the opportunity for prevention with timely testing and treatment. In addition, the treatment regimen in LTBI is shorter and more effective than it was in the past.
This guide is intended for primary care providers who care for patients who may be at risk for latent TB infection (LTBI) to progress to TB disease. Recommendations include: Treatment Regimens, Special Considerations in the Treatment of LTBI, Adverse Effects of Drugs Used to Treat LTBI, Patient Monitoring and Education During Treatment, Assessing Adherence, Techniques to Improve Adherence, and Post-Treatment Follow-Up. Most recent recommendations also include the use of interferon-gamma release assays (IGRAs).
Page 5 of 6 · Total posts: 0←First 4 5 6 Last→